LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

Home・Listă Acțiuni・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Deschisă

SectorSănătate

66.94 -2.05

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

66.7

Maxim

68.74

Indicatori cheie
By Trading Economics
Venit	292M 150M
Vânzări	-75M 377M
P/E Medie Sector	24.112 50.102
EPS	1.221
Marjă de profit	39.832
Angajați	423
EBITDA	-63M 218M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+17.23% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	501M 8.2B
Deschiderea anterioară	68.99
Închiderea anterioară	66.94

Sentimentul știrilor

By Acuity

34%

66%

82 / 344 Clasament în Healthcare

Halozyme Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

28 mai 2026, 22:47 UTC

Câștiguri

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mai 2026, 20:45 UTC

Câștiguri

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mai 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mai 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mai 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mai 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mai 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mai 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 mai 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mai 2026, 22:37 UTC

Market Talk

Achiziții, Fuziuni, Preluări

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mai 2026, 22:04 UTC

Achiziții, Fuziuni, Preluări

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mai 2026, 22:04 UTC

Achiziții, Fuziuni, Preluări

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mai 2026, 21:12 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mai 2026, 21:00 UTC

Câștiguri

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mai 2026, 20:57 UTC

Câștiguri

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mai 2026, 20:55 UTC

Câștiguri

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 mai 2026, 20:48 UTC

Acțiuni populare

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mai 2026, 20:34 UTC

Câștiguri

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mai 2026, 20:31 UTC

Câștiguri

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mai 2026, 20:28 UTC

Câștiguri

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mai 2026, 20:26 UTC

Câștiguri

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mai 2026, 20:20 UTC

Câștiguri

Costco 3Q Membership Fees $1.37B

28 mai 2026, 20:20 UTC

Câștiguri

Costco 3Q Net Sales $69.15B

28 mai 2026, 20:19 UTC

Câștiguri

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mai 2026, 20:19 UTC

Câștiguri

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mai 2026, 20:17 UTC

Câștiguri

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mai 2026, 20:17 UTC

Câștiguri

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparație

Modificare preț

Halozyme Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

17.23% sus

Prognoză pe 12 luni

Medie 80.48 USD 17.23%

Maxim 96 USD

Minim 66.41 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHalozyme Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Halozyme Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

82 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.